Cargando…

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma

BACKGROUND: Survival heterogeneity and limited trial follow-up present challenges for estimating lifetime benefits of oncology therapies. This study used CheckMate 067 (NCT01844505) extended follow-up data to assess the predictive accuracy of standard parametric and flexible models in estimating the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Federico Paly, Victoria, Kurt, Murat, Zhang, Lirong, Butler, Marcus O., Michielin, Olivier, Amadi, Adenike, Hernlund, Emma, Johnson, Helen M., Kotapati, Srividya, Moshyk, Andriy, Borrill, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958523/ https://www.ncbi.nlm.nih.gov/pubmed/35356551 http://dx.doi.org/10.1177/23814683221089659

Ejemplares similares

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
por: Toor, Kabirraaj, et al.
Publicado: (2021)

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
por: Batteson, Rachael, et al.
Publicado: (2019)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
por: Branchoux, S., et al.
Publicado: (2021)

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

Survival extrapolation using the poly-Weibull model
por: Demiris, Nikolaos, et al.
Publicado: (2015)

Survival extrapolation in the presence of cause specific hazards
por: Benaglia, Tatiana, et al.
Publicado: (2015)

Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation
por: Cooney, Philip, et al.
Publicado: (2023)

How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness
por: Kearns, Ben, et al.
Publicado: (2019)

survextrap: a package for flexible and transparent survival extrapolation
por: Jackson, Christopher H.
Publicado: (2023)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

INES: Interactive tool for construction and extrapolation of partitioned survival models
por: Gimeno-Ballester, Vicente, et al.
Publicado: (2023)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study
por: Kearns, Benjamin, et al.
Publicado: (2022)

Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
por: Lee, D., et al.
Publicado: (2018)

Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
por: Lee, D., et al.
Publicado: (2018)

Extrapolation of Survival Curves from Cancer Trials Using External Information
por: Guyot, Patricia, et al.
Publicado: (2016)

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
por: Zhang, Ying, et al.
Publicado: (2015)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study
por: Gallacher, Daniel, et al.
Publicado: (2020)

Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness
por: Latimer, Nicholas R, et al.
Publicado: (2022)

Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors
por: Badami, Sunil, et al.
Publicado: (2018)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
por: Jackson, Christopher, et al.
Publicado: (2016)

An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data
por: Vickers, Adrian
Publicado: (2019)

A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data
por: Tremblay, Gabriel, et al.
Publicado: (2015)

Evolving impact of long-term survival results on metastatic melanoma treatment
por: Michielin, Olivier, et al.
Publicado: (2020)

Societal preferences for adjuvant melanoma health states: UK and Australia
por: Middleton, Mark R., et al.
Publicado: (2017)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
por: Wang, Meihua, et al.
Publicado: (2019)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
por: Villa-Crespo, Lorena, et al.
Publicado: (2022)

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
por: Ouwens, Mario J. N. M., et al.
Publicado: (2019)

Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
por: Lin, Zhen, et al.
Publicado: (2020)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_97vmvm1d85e9pkjfemqp7bckgl